The company expects to launch the product in the US in the third quarter of 2012.
BINOSTO is a treatment option for those patients who have difficulty with tablets, the company said.
EffRx chairman and CEO Christer Rosen said BINOSTO is meant for those patients who have difficulty with tablets the proven fracture risk reduction of alendronate in a pleasant tasting and easy-to-swallow buffered solution.